ZA200800906B - Methods of treatment using hydroquinone ansamycins - Google Patents
Methods of treatment using hydroquinone ansamycinsInfo
- Publication number
- ZA200800906B ZA200800906B ZA200800906A ZA200800906A ZA200800906B ZA 200800906 B ZA200800906 B ZA 200800906B ZA 200800906 A ZA200800906 A ZA 200800906A ZA 200800906 A ZA200800906 A ZA 200800906A ZA 200800906 B ZA200800906 B ZA 200800906B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzoquinone
- hydroquinone
- treatment
- methods
- ansamycins
- Prior art date
Links
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 title abstract 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/180,314 US20060019941A1 (en) | 2003-12-23 | 2005-07-13 | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200800906B true ZA200800906B (en) | 2009-07-29 |
Family
ID=37637939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200800906A ZA200800906B (en) | 2005-07-13 | 2006-07-13 | Methods of treatment using hydroquinone ansamycins |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060019941A1 (es) |
| EP (1) | EP1904057B1 (es) |
| JP (1) | JP2009501234A (es) |
| KR (1) | KR20080030093A (es) |
| CN (1) | CN101267816A (es) |
| AT (1) | ATE451919T1 (es) |
| AU (1) | AU2006268196A1 (es) |
| BR (1) | BRPI0612870A2 (es) |
| CA (1) | CA2612506A1 (es) |
| DE (1) | DE602006011161D1 (es) |
| ES (1) | ES2337397T3 (es) |
| IL (1) | IL188355A0 (es) |
| MX (1) | MX2007016469A (es) |
| NO (1) | NO20080304L (es) |
| WO (1) | WO2007009007A2 (es) |
| ZA (1) | ZA200800906B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2547343C (en) | 2003-12-23 | 2013-05-14 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins for the treatment of cancer |
| WO2006098761A2 (en) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Hsp90 inhibitors, methods of making and uses therefor |
| WO2007002093A2 (en) * | 2005-06-21 | 2007-01-04 | Infinity Discovery, Inc. | Ansamycin formulations and methods of use thereof |
| FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
| PE20081506A1 (es) | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| WO2008128063A1 (en) * | 2007-04-12 | 2008-10-23 | Infinity Discovery, Inc. | Hydroquinone ansamycin formulations |
| EP2190291B1 (en) | 2007-08-23 | 2015-10-14 | The Regents of The University of Colorado, A Body Corporate | Hsp90 inhibitors with modified toxicity |
| US20090258869A1 (en) * | 2008-02-08 | 2009-10-15 | The Regents Of The University Of California | Methods and compounds for treatment or prevention of substance-related disorders |
| AU2009283157B2 (en) * | 2008-08-21 | 2015-02-26 | Alvine Pharmaceuticals, Inc. | Formulation for oral administration of proteins |
| WO2010045442A1 (en) * | 2008-10-15 | 2010-04-22 | Infinity Discovery, Inc. | Ansamycin hydroquinone compositions |
| US20120108563A1 (en) * | 2009-05-19 | 2012-05-03 | Infinity Pharmaceuticals, Inc. | Methods Of Treating Liposarcoma |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| US8945627B2 (en) | 2011-05-05 | 2015-02-03 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
| US9603829B2 (en) | 2011-11-14 | 2017-03-28 | The Regents Of The University Of Colorado, A Body Corporate | HSP90 inhibitors with modified toxicity |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| RU2701645C2 (ru) | 2014-05-01 | 2019-09-30 | Ионис Фармасьютикалз, Инк. | Композиции и способы модулирования экспрессии фактора комплемента в |
| CN114259564B (zh) * | 2021-11-30 | 2023-03-14 | 清华大学 | Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用 |
| CN115227692A (zh) * | 2022-09-05 | 2022-10-25 | 中国医学科学院基础医学研究所 | Reblastatin在制备治疗慢性惊厥的药物中的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| DE3234203A1 (de) * | 1981-09-17 | 1983-07-07 | Takeda Chemical Industries, Ltd., Osaka | Macbecin-derivate und deren herstellung |
| US4762857A (en) * | 1986-05-30 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
| HU9401936D0 (en) * | 1992-01-06 | 1994-09-28 | Pfizer | Process and uses for 4,5-diohydrogeldanamycin and its hydroquinone |
| US5387584A (en) * | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
| EP0706516A1 (en) * | 1993-06-29 | 1996-04-17 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| ES2268068T3 (es) * | 2001-03-30 | 2007-03-16 | The Usa, Represented By The Secretary, Dept. Of Health And Human Services National Institutes Health | Derivado de geldanamicina util para el tratamiento del cancer. |
| WO2003013430A2 (en) * | 2001-08-06 | 2003-02-20 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| DE60327994D1 (de) * | 2002-02-08 | 2009-07-30 | Conforma Therapeutics Corp | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
| CA2547343C (en) * | 2003-12-23 | 2013-05-14 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins for the treatment of cancer |
| WO2006098761A2 (en) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Hsp90 inhibitors, methods of making and uses therefor |
-
2005
- 2005-07-13 US US11/180,314 patent/US20060019941A1/en not_active Abandoned
-
2006
- 2006-07-13 KR KR1020087003410A patent/KR20080030093A/ko not_active Application Discontinuation
- 2006-07-13 DE DE602006011161T patent/DE602006011161D1/de active Active
- 2006-07-13 JP JP2008521582A patent/JP2009501234A/ja active Pending
- 2006-07-13 EP EP06787067A patent/EP1904057B1/en active Active
- 2006-07-13 CA CA002612506A patent/CA2612506A1/en not_active Abandoned
- 2006-07-13 MX MX2007016469A patent/MX2007016469A/es not_active Application Discontinuation
- 2006-07-13 CN CNA2006800335526A patent/CN101267816A/zh active Pending
- 2006-07-13 AT AT06787067T patent/ATE451919T1/de not_active IP Right Cessation
- 2006-07-13 ZA ZA200800906A patent/ZA200800906B/xx unknown
- 2006-07-13 BR BRPI0612870-0A patent/BRPI0612870A2/pt not_active IP Right Cessation
- 2006-07-13 ES ES06787067T patent/ES2337397T3/es active Active
- 2006-07-13 WO PCT/US2006/027113 patent/WO2007009007A2/en active Application Filing
- 2006-07-13 AU AU2006268196A patent/AU2006268196A1/en not_active Abandoned
-
2007
- 2007-12-24 IL IL188355A patent/IL188355A0/en unknown
-
2008
- 2008-01-16 NO NO20080304A patent/NO20080304L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0612870A2 (pt) | 2010-11-30 |
| MX2007016469A (es) | 2008-04-22 |
| ES2337397T3 (es) | 2010-04-23 |
| CA2612506A1 (en) | 2007-01-18 |
| IL188355A0 (en) | 2008-08-07 |
| US20060019941A1 (en) | 2006-01-26 |
| EP1904057B1 (en) | 2009-12-16 |
| ATE451919T1 (de) | 2010-01-15 |
| EP1904057A2 (en) | 2008-04-02 |
| AU2006268196A1 (en) | 2007-01-18 |
| DE602006011161D1 (de) | 2010-01-28 |
| NO20080304L (no) | 2008-02-29 |
| WO2007009007A3 (en) | 2007-05-03 |
| CN101267816A (zh) | 2008-09-17 |
| JP2009501234A (ja) | 2009-01-15 |
| WO2007009007A2 (en) | 2007-01-18 |
| KR20080030093A (ko) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200800906B (en) | Methods of treatment using hydroquinone ansamycins | |
| NO20062707L (no) | Analoger av benzokinon-inneholdende ansamyciner for behandling av kreft | |
| MY153957A (en) | Novel compounds 951: a biphenyloxypropanoic acid as crth2 modulator and intermediates | |
| TN2010000125A1 (en) | Substituted biphenyl gpr40 modulators | |
| WO2008024304A3 (en) | Compounds for treatment of proliferative disorders | |
| BRPI0519265A2 (pt) | composiÇÕes incluindo ferro | |
| MX2011012277A (es) | Variantes de peptidos natriureticos de tipo c. | |
| TW200612892A (en) | Novel compounds | |
| TW200407305A (en) | Novel compounds | |
| HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
| MX2008010671A (es) | Derivados de cinolina como inhibidores de fosfodiesterasa 10. | |
| HK1073996A1 (en) | Use of adapalene for the treatment of dermatological disorders | |
| MY174896A (en) | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | |
| UA94067C2 (en) | Method of activating a photosensitizer | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201001286A1 (ru) | Комбинированное применение 25-гидроксивитамина d3 и витамина d3 для повышения плотности минерального вещества костей и для лечения остеопороза | |
| MX2009011878A (es) | Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina. | |
| MX2010003948A (es) | N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas. | |
| IN2014CN02273A (es) | ||
| TW200633977A (en) | Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives | |
| TW200728258A (en) | Novel compounds | |
| MX2010002042A (es) | Derivados de 1,3-dihidroisoindol. | |
| CY1109569T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
| EA201001586A1 (ru) | Соединения и композиции в качестве ингибиторов itpkb | |
| CY1111730T1 (el) | Διαδικασια για την παρασκευη γκαμπαπεντινης |